SCHEMBL2415292

SCHEMBL2415292

CC(C)c1ccc(-c2cnc(OCCc3csc(SC(C)(C)C(=O)O)n3)nc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 7/20 0.38
PPARG P37231 3/20 0.38
PPARD Q03181 2/20 0.38
SLC22A12 Q96S37 6/20 0.35
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
NFKB1 P19838 1/20 0.34
RAB9A P51151 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
DGAT1 O75907 1/20 0.33
EGLN1 Q9GZT9 2/20 0.32
VEGFA P15692 1/20 0.32
FLT1 P17948 1/20 0.32
LMNA P02545 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
EIF4E P06730 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2414730 0.90 SLC22A12 (0.40) PPARASLC22A12ALDH1A1MAPTNPC1
SCHEMBL2412565 0.88 SLC22A12 (0.42) PPARAPPARGPPARDSLC22A12EIF4E
SCHEMBL2411181 0.87 PPARA (0.36) PPARAPPARGPPARDSLC22A12MAPT
SCHEMBL2411276 0.87 SLC22A12 (0.42) PPARAPPARGSLC22A12ALDH1A1MAPT
SCHEMBL2417090 0.85 PPARA (0.36) PPARASLC22A12MAPTDGAT1EIF4E
SCHEMBL2412787 0.85 SHMT2 (0.39) PPARAPPARGPPARDSLC22A12DGAT1
SCHEMBL2414035 0.84 DGAT1 (0.39) PPARASLC22A12RAB9ADGAT1LMNA
SCHEMBL2414304 0.84 PPARA (0.40) PPARAPPARGPPARDSLC22A12ALDH1A1
SCHEMBL2410912 0.83 PPARA (0.39) PPARAPPARGSLC22A12MAPTEGLN1
SCHEMBL2415563 0.81 PPARA (0.42) PPARAPPARGPPARDALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG PPARA 1/4885PPARG 3/4885PPARD 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.